BCs are classified as human epidermal growth factor receptor 2 (Her-2), luminal A, luminal B, and triple negative BC, according to the status of the progesterone receptor (PR), estrogen receptor (ER) and Her-2 receptor (Yeo and Guan, 2017). This evidence concerns the gene ERBB2 and breast cancer.